Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.
(@nhlbiforumadministrator1)

Goal 2: Reduce Human Disease

National cardiac arrest registry

Cardiac arrest registries are needed to measure and improve the process and outcome of resuscitation care and provide a platform for exploring insight into risk factors, prognosis, and the effectiveness of interventions for out-of-hospital (OHCA) and in-hospital cardiac arrest (IHCA).

Voting

-8 net votes
9 up votes
17 down votes
Active
(@jennifergrobinson)

Goal 2: Reduce Human Disease

How can we implement what we already know for ASCVD prevention?

We have a number of highly effective evidence-based interventions that have been shown to reduce ASCVD events - statins, BP drugs, aspirin, acute care. Yet large proportions of high risk population groups are not taking evidence-based treatment. Numerous interventions have been tried at multiple levels from the individual patient to the federal government payors. What are the best practices? How can we systematically ...more »

Voting

-9 net votes
3 up votes
12 down votes
Active
(@gabrielegrunig)

Goal 2: Reduce Human Disease

New analysis methods for research using animal models

The idea that 'animal models can faithfully predict the outcomes in human clinical trials of new medicines and treatments' is highly compelling. However, due to differences (biological and non-biological) between humans and animals this goal can likely not be achieved. Not only are animals genetically different from humans, everything else is different too. Even if living quarters are shared (e.g. house pet animals), ...more »

Voting

-12 net votes
7 up votes
19 down votes
Active
(@ahenn0)

Goal 2: Reduce Human Disease

Making It Real: Affordable Physiologically Relevant In Vitro Environments

We have done the best we can to mimic the human internal environment in vitro for the discovery, testing, and validation of therapeutics, but there is a critical need to do better. The use of more complex cell-based in vitro models is the result of the recognition of how little predictive power there is in current experimental conditions, even with animal models. With an in vitro environment that goes beyond temperature ...more »

Voting

-4 net votes
10 up votes
14 down votes
Active
(@kathi0)

Goal 2: Reduce Human Disease

Correlation of genetic modifiers and cardiopulmonary fibrosis/dysfunction in Duchenne

What are the protective genetic modifiers that may be associated with a Duchenne phenotype more resistant to the development of cardiac and pulmonary fibrosis and subsequent pulmonary/cardiac dysfunction? . Are there genetic modifiers that may ameliorate or enhance the onset of cardiac and/or pulmonary dysfunction?

Voting

-2 net votes
4 up votes
6 down votes
Active
(@hloree)

Goal 2: Reduce Human Disease

Devices for Immediate and Complete Peripheral Artery Occlusion

Approximately 50,000 peripheral artery embolization procedures are performed annually in the U.S. for a variety of clinical indications including stopping life-threatening bleeding; reducing blood flow to cancerous tumors; and diverting blood away from arterial aneurysms, arteriovenous fistulas, and other vascular malformations. Most of these procedures involve the endovascular implantation of wire coils or wire mesh ...more »

Voting

-8 net votes
4 up votes
12 down votes
Active
(@gcioffi)

Goal 2: Reduce Human Disease

Iron Metabolism in thalassemia syndromes, and other rare and common anemias

Thanks to elegant work since the 1990s, many details of the role of iron regulation and metabolism have been elucidated. Recent efforts in academic and pharmaceutical laboratories aim to translate these discoveries into therapies that may alleviate anemia in iron-refractory states (including anemia of inflammation and congenital disorders), and may have important therapeutic effects in non-transfusion-dependent thalassemia, ...more »

Voting

40 net votes
55 up votes
15 down votes
Active
(@nareg.roubinian)

Goal 2: Reduce Human Disease

The potency and safety of transfusable red blood cells

Can we identify approaches to improve potency and/or safety of transfusable RBCs? 42 day pre-transfusion storage of RBCs maximizes utilization, while minimizing waste. However, RBCs undergo changes during collection, manipulation and storage that may reduce their potency or safety. Progress in understanding markers that predict transfusion success at the time of collection and with storage remains slow. New technologies ...more »

Voting

14 net votes
31 up votes
17 down votes
Active
(@dayam0)

Goal 2: Reduce Human Disease

Benefits of intraosseous access on outcomes from OHCA

Vascular access is a challenge in the setting of out-of-hospital cardiac arrest (OHCA). The failure of medications to impact outcomes may be in part related to the delay in drug delivery from the IV route. EMS systems have adopted intraosseous (IO) access but it is not clear if these are affecting outcome and there has been no large RCT. The current IO access devices are expensive and use different routes (sternal, tibia, ...more »

Voting

0 net votes
2 up votes
2 down votes
Active